Harvard Bioscience, Inc. (HBIO) vs Nephros Inc. (NEPH)
- Harvard Bioscience, Inc. HBIO 8.09 −2.65%
- Nephros Inc. NEPH 3.65 +3.99%
Harvard Bioscience, Inc. and Nephros Inc. are both Medical Instruments & Supplies companies. Harvard Bioscience, Inc. and Nephros Inc. are of similar size ($38.1M and $37.8M). Harvard Bioscience, Inc. has negative trailing earnings, so its P/E is not meaningful; Nephros Inc. trades at 23.4×. Nephros Inc. grew revenue faster over the last twelve months: 24.2% against −1.06%. Nephros Inc. has the higher net margin (8.38% vs −11.9%) and the higher return on invested capital (14.1% vs −0.41%). Across the 19 metrics below, Nephros Inc. leads on 15 and Harvard Bioscience, Inc. on 4.
Valuation
Profitability
| Metric | HBIO | NEPH | Medical Instruments & Supplies median |
|---|---|---|---|
| Gross margin | 58.16% | 61.26% | 54.29% |
| Operating margin | (0.28%) | 7.92% | 1.07% |
| Net margin | (11.86%) | 8.38% | (1.61%) |
| Free cash flow margin | (2.09%) | (3.19%) | 1.08% |
| Return on equity | (89.95%) | 16.10% | (1.32%) |
| Return on assets | (13.32%) | 12.39% | 0.00% |
| Return on invested capital | (0.41%) | 14.11% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack